title: Treatment of obesity in 2015.
abstract: Obesity is a major health priority in the United States, as well as globally. It is associated with multiple comorbidities and reduced life expectancy. Effective management of obesity involves producing an intervention plan tailored to the individual patient. Potential contributory factors to weight gain, including dietary habits, physical inactivity, associated medical conditions, and medications, should be identified and addressed. Lifestyle interventions comprising diet modification, physical activity, and behavior therapy are foundational to the management of obesity. Caloric restriction is the most important component in achieving weight loss through negative energy balance, whereas sustained physical activity is important in maintaining the weight loss. Adjunctive therapies in the form of pharmacotherapy and bariatric surgery are required in patients who do not achieve targeted weight loss and health goals with lifestyle interventions. Currently there are 3 drugs approved for long-term management of obesity, orlistat, phentermine/topiramate extended release, and lorcaserin, and there are 2 on the horizon, bupropion/naltrexone and liraglutide. Bariatric surgery is an effective strategy recognized to produce durable weight loss with amelioration of obesity-related comorbidities and should be considered a treatment option in eligible patients.
authors.affiliation: Center for Weight Management and Metabolic Clinical Research, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York.
authors.forename: Alpana P
authors.initials: AP
authors.lastname: Shukla
authors.forename: William I
authors.initials: WI
authors.lastname: Buniak
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Aronne
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D050110:Bariatric Surgery; D001552:Benzazepines / Q000627:therapeutic use; D031204:Caloric Restriction; D004338:Drug Combinations; D015444:Exercise; D005247:Feeding Behavior; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D009765:Obesity / Q000628:therapy*; D000077403:Orlistat; D010645:Phentermine / Q000627:therapeutic use; D040242:Risk Reduction Behavior; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D004338:Drug Combinations; D007783:Lactones; D000077236:Topiramate; D005632:Fructose; C506658:lorcaserin; D000077403:Orlistat; D010645:Phentermine